174184-13-5

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 3-broMo-4-oxo-, phenylMethyl ester
• Synonyms: 1-Piperidinecarboxylic acid, 3-broMo-4-oxo-, phenylMethyl ester;Benzyl 3-bromo-4-oxopiperidine-1-carboxylate;3-Bromo-4-oxo-piperidine-1-carboxylicacidbenzylester;1-Cbz-3-bromo-4-oxo-piperidine
• CAS NO: 174184-13-5
• Molecular Formula: C₁₃H₁₄BrNO₃
• Molecular Weight: 312.15916
• Mol File: 174184-13-5.mol

Chemical Properties

• Boiling Point: 423.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.510±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -3.40±0.40(Predicted)
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 3-broMo-4-oxo-, phenylMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 3-broMo-4-oxo-, phenylMethyl ester(174184-13-5)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 3-broMo-4-oxo-, phenylMethyl ester(174184-13-5)

Safety Data

• Hazardous Substances Data: 174184-13-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Piperidinecarboxylic acid, 3-brom-4-oxo-, phenylmethyl ester is used as a therapeutic agent for treating anxiety, insomnia, and other mood disorders. Its anxiolytic and mood-enhancing properties make it a valuable asset in the management of these conditions.
Used in Nootropic Applications:
Phenibut is used as a cognitive enhancer to improve mental performance, focus, and memory. Its ability to reduce stress and promote relaxation makes it a popular choice among individuals seeking to enhance their cognitive abilities.
Used in Research and Development:
1-Piperidinecarboxylic acid, 3-brom-4-oxo-, phenylmethyl ester is utilized in scientific research to study the effects of GABAergic compounds on the brain and their potential applications in the treatment of neurological and psychiatric disorders.

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 

Downstream Products

• 733757-99-8 2-(4-methylsulfanyl-phenyl)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid benzyl ester 
• 901309-20-4 benzyl 2-(2-(2-tert-butylphenoxy)pyridin-3-ylamino)-6,7-dihydrothiazolo-[5,4-c]pyridine-5(4H)-carboxylate 
• 733758-00-4 2-(4-methanesulfonyl-phenyl)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid benzyl ester 
• 733757-97-6 2-(4-methanesulfonyl-phenyl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine 
• 853784-26-6 2-(4-methylsulfanyl-phenyl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine 
• 853784-25-5 2-(4-fluorophenyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 1030122-16-7 2-methyl-4,5,6,7-tetrahydro-thiazolo(5,4-c)pyridinium bromide 
• 1354910-20-5 2-(4-methoxy-phenyl)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid benzyl ester 
• 1354905-82-0 3-[2-(4-(2-fluoro-benzyloxy)-phenyl)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-yl]-propionic acid 
• 1354910-22-7 3-[2-(4-(2-fluoro-benzyloxy)-phenyl)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-yl]-propionic acid t-butyl ester 
• 1354910-21-6 3-[2-(4-hydroxy-phenyl)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-yl]-propionic acid t-butyl ester 
• 1174738-34-1 4-(4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine-2-yl)-phenol 

Relevant articles and documents

CHEMICAL COMPOUNDS AS ANTIBIOTICS

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p? q, L, ?, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS

The present invention relates to a fused heterocyclic derivative of the formula (I) The variables R1-R4, z, A, Q, X and Y are as defined in the claims. The following heterocycles are exemplified substructures of formula (I): The compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor), More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of cognitive disorders, age-relate cognitive decline and dementia.

ALKYLAMINOPYRIDINE DERIVATIVE

The present invention relates to a compound that is useful for treatment of, for example, hypertension, arteriosclerosis, bulimia and obesity because of having an antagonistic action to a neuropeptide Y receptor and is represented by formula (I) [wherein R1 represents hydrogen, cyano, or the like; R represents a group represented by formula (II); X1 represents C1-4 lower alkylene or the like; X2 represents lower alkylene or the like; and Het represents a 5-membered heteroaromatic ring that has at least one nitrogen atom and, in addition, one or two hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms] or to a pharmaceutically acceptable salt thereof.

PYRAZOLE COMPOUNDS AND USE THEREOF

The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

Heteroaryl compounds as P2Y1 receptor inhibitors

The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole

A series of β-aminoacylpiperidines bearing various fused five-membered heterocyclic rings was synthesized as dipeptidyl peptidase IV inhibitors. Potent and relatively selective inhibition could be obtained, depending on choice of heterocycle, regioisomerism, and substitution. In particular, one analog (74, DPP-IV IC50 = 26 nM) exhibited good oral bioavailability and acceptable half-life in the rat, albeit with rather high clearance.

GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS

The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors in order to treat diseases modulated by 5-HT5 receptor activity, especially treat neurodegenerative and neuropsychiatric disorders and the signs, symptoms, and malfunctions associated therewith.